ress Mail" Mail Label No. EL 743812102 US

1653

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	J. Gregor Sutcliffe et al.	)
Serial No.	09/735,138	)
Filed:	December 12, 2000	)
For:	HYPOTHALAMUS-SPECIFIC POLYPEPTIDES	)
Examiner:	Anne-Marie Baker	)

Group Art Unit: 1653

Atty. Docket No.: TSRI 548.1 Div. 1

AMENDMENT AND RESPONSE UNDER 37 CFR §1.821(d)

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

Sir:

In response to the Office communication on the above-identified application dated July 8, 2002, please amend this application as follows.

In the Specification:

Rewrite the paragraph beginning on page 4, line 14, to read:

-- Fig. 5 shows a comparison of rat and mouse cDNA and amino acid sequences corresponding to clone 35 and the amino acid sequence of the peptide hormone secretin. A. The amino acid sequence is listed on the top line (rat SEQ ID NO: 1; mouse SEQ ID NO: 2), the rat nucleotide sequence (SEQ ID NO: 14) on the second line and the mouse nucleotide sequence (SEQ ID NO: 15) is listed on the third line. Differences in nucleotide sequences are indicated by asterisks below each different base, amino acid differences are indicated by alternatives (rat/mouse) listed above the encoding triplets. Tandem basic amino acids (putative sites for proteolytic maturation) are indicated in bold italics, as is the serine residue most likely to represent the end of the secretion signal. B. Alignment of hcrt1 and hcrt2 amino acid sequences (SEQ ID NO: 7 and SEQ ID NO: 9, respectively) with the amino acid sequence of secretin (SEQ ID NO: 21). The first 9 amino acid residues of secretin have been repeated to indicate apparent circular permutation. The identities between the hypocretins and members of the glucagon/vasoactive intestinal